Mead Johnson Set Loose To Navigate Market, Shifting Economic Winds
This article was originally published in The Pink Sheet Daily
Executive Summary
The premium status of MJN’s Enfamil products could be a liability in an economic climate that drives consumers toward value brands – even in the traditionally resistant category of infant formula.
You may also be interested in...
Otsuka Plans $2.8 Billion IPO To Feed Global Expansion
Otsuka Holdings Co., the parent of Japanese drug maker Otsuka Pharmaceutical Co. Ltd., has scheduled its long-planned initial public offering for December 15
Otsuka Plans $2.8 Billion IPO To Feed Global Expansion
Still fueled by growth of the anti-psychotic Abilify, the Japanese pharma's parent company plans to list on the Tokyo Stock Exchange on December 15.
Otsuka Plans $2.8 Billion IPO To Feed Global Expansion
Still fueled by growth of the anti-psychotic Abilify, the Japanese pharma's parent company plans to list on the Tokyo Stock Exchange on December 15.